Salarius Pharmaceuticals (NASDAQ:SLRX – Get Free Report) released its quarterly earnings data on Friday. The company reported ($1.81) earnings per share for the quarter, FiscalAI reports.
Salarius Pharmaceuticals Stock Down 0.8%
NASDAQ:SLRX traded down $0.01 during midday trading on Friday, hitting $1.20. The company had a trading volume of 2,190,965 shares, compared to its average volume of 599,083. The company has a market capitalization of $612,000.00, a PE ratio of -0.03 and a beta of 0.40. Salarius Pharmaceuticals has a 52-week low of $0.91 and a 52-week high of $108.00. The stock’s fifty day moving average price is $3.90 and its 200-day moving average price is $8.27.
Analyst Ratings Changes
Separately, Wall Street Zen raised Salarius Pharmaceuticals to a “sell” rating in a report on Friday, August 22nd.
Salarius Pharmaceuticals Company Profile
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
See Also
- Five stocks we like better than Salarius Pharmaceuticals
- 10 Best Airline Stocks to Buy
- Are These 3 Oversold Tech Giants Ready to Rebound?
- What is the Australian Securities Exchange (ASX)
- If You Wait for the Dip, Micron Technology Could Leave You Behind
- What is a Death Cross in Stocks?
- 3 Stocks Quietly Powering the AI and Tech Revolution
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
